{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-069611","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-06-17T20:01:15+00:00","discovered_at":"2026-06-17T20:02:00.321470+00:00","generated_at":"2026-06-17T20:03:07.378061+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"INmune Bio stockholders approve Third Amended 2021 Stock Incentive Plan, increasing share reserve to ~9.16M shares","bullets":["Stockholders approved Third Amended 2021 Stock Incentive Plan, increasing share reserve from 6.5M to 9,158,525 shares.","Plan includes evergreen provision: annual auto-increase on first trading day of 2027-2031, up to 10% of outstanding shares.","All five director nominees elected: David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, Marcia Allen.","Ratification of CBIZ CPAs P.C. as independent auditor for FY2026 approved with 17,293,255 votes for.","Broker non-votes: 8,501,317 shares on director elections and plan vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-069611","json":"https://secwatch.observer/filing/0001213900-26-069611.json","markdown":"https://secwatch.observer/filing/0001213900-26-069611.md","text":"https://secwatch.observer/filing/0001213900-26-069611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/0001213900-26-069611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/ea0295129-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:03:07.378061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40af4112d5709e3864530295954c8724cfb62228","claim":"Inmune Bio, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.","evidence_excerpt":"Proposal One: Election of Directors. Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company’s stockholders and until his or her successor is elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes David Moss 6,834,995 2,120,682 8,501,317 J. Kelly Ganjei 5,955,609 3,000,068 8,501,317 Tim Schroeder 6,622,916 2,332,761 8,501,317 Scott Juda, JD 7,508,310 1,447,367 8,501,317 Marcia Allen 6,342,910 2,612,767 8,501,317 1","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/0001213900-26-069611-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"86873315b1893e534723c428709d9d997aa1052e","claim":"Inmune Bio, Inc. shareholders approved Ratification of Appointment of Independent Auditor at the 2026-06-16 meeting.","evidence_excerpt":"Proposal Two: Ratification of Appointment of Independent Auditor. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent auditors for the fiscal year ending December 31, 2026. For Against Abstentions Broker Non-Votes 17,293,255 107,064 56,675 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/0001213900-26-069611-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"f54e70108c398f1f46dc858a7068acf8f38ee114","claim":"Inmune Bio, Inc. shareholders approved Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan at the 2026-06-16 meeting.","evidence_excerpt":"Proposal Three: Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan. As noted above, the stockholders approved the Amended Plan. For Against Abstentions Broker Non-Votes 6,085,086 2,775,224 95,367 8,501,317","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/0001213900-26-069611-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}